Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 84 peer-reviewed journal articles Updated
Neurology · Multiple Sclerosis

Progressive Relapsing Multiple Sclerosis (PRMS) and Modern Progressive MS: A Patient Guide

At a Glance

Progressive relapsing multiple sclerosis is an older term. Doctors now classify progressive MS as primary progressive or secondary progressive based on its history, then describe whether it is active, progressing, or both to guide treatment and rehabilitation.

Receiving a diagnosis of Progressive Relapsing Multiple Sclerosis (PRMS) or another form of progressive MS can be overwhelming, particularly because the language doctors use to describe the condition has changed significantly in recent years. Historically, Progressive Relapsing MS (PRMS) was used to describe a specific pattern where someone experienced a steady worsening of symptoms from the very beginning, while also having occasional sudden attacks, known as relapses. Today, experts have retired the term PRMS in favor of a more precise framework that describes how the disease is behaving right now [1][2].

In modern care, your diagnosis is viewed through two main lenses: the underlying course of the disease and its current level of activity. If your MS was progressive from the very first symptom, it is now classified as Primary Progressive MS (PPMS); if it followed a phase of attacks and recoveries, it is called Secondary Progressive MS (SPMS) [3]. Within these categories, doctors look for activity, which refers to new inflammation seen as a clinical relapse or a new spot on an MRI. This is distinct from progression, which is the slow, steady accumulation of disability [4][5]. These are descriptions of your condition at a specific time, and your “active” or “progressing” status can change over the years.

Managing progressive MS today focuses on addressing both of these dimensions simultaneously. Medications known as disease-modifying therapies (DMTs)—such as ocrelizumab for adult PPMS or siponimod for active SPMS—can be used to help slow the rate of change and reduce the frequency of new inflammatory activity [6][7]. While these treatments are effective at slowing the disease, they are rarely able to stop it entirely or reverse existing damage, making early and consistent management vital [8][9]. For those with non-active progression, treatment decisions are highly individualized based on age, disease duration, and safety considerations.

Living well with progressive MS requires more than just medication; it requires a dedicated multidisciplinary care team. This team typically includes neurologists, physical and occupational therapists, urologists, and other specialists who work together to manage daily symptoms like fatigue, mobility challenges, and spasticity [10][11]. By combining advanced treatments that target the biology of the disease with personalized rehabilitation and symptom care, the focus of modern MS management is on preserving your function and improving your quality of life for as long as possible [12][13].

In this guide

6 chapters

01

Understanding Your Diagnosis: From PRMS to Modern Terminology

Learn how progressive relapsing MS is classified today. Understand PPMS, SPMS, activity, progression, MRI findings, and what changed in modern MS terminology.

02

Daily Realities: Managing Symptoms and Knowing the Warning Signs

Learn how progressive-relapsing MS affects walking, spasticity, fatigue, cognition, and bladder function, and when a relapse or sudden symptom needs urgent care.

03

The Biology of Change: How Activity and Progression Work

Learn how progressive MS biology drives activity and disability, including relapses, MRI lesions, PIRA, chronic inflammation, neurodegeneration, and myelin repair.

04

The Diagnostic Toolkit: MRIs, Tests, and Monitoring

Learn how progressive MS is diagnosed and monitored with MRI findings, lumbar puncture results, disability tests, spinal cord atrophy, and blood biomarkers.

05

Treatment Options: Managing Progressive MS with Medications

Learn about progressive MS medications, including ocrelizumab and siponimod; review infection risks, monitoring, vaccines, and non-active disease care.

06

Planning for the Future: Prognosis and Your Care Team

Learn what affects progressive MS prognosis, how PIRA and MRI findings relate to progression, and which specialists can support long-term care planning.

Common questions in this guide

Is progressive relapsing MS still used as a separate diagnosis?
Progressive relapsing MS, or PRMS, is an older term that is no longer used as a separate MS category. MS that was progressive from the first symptom is now generally called primary progressive MS (PPMS), while progression after an earlier relapsing phase is called secondary progressive MS (SPMS).
What is the difference between active MS and progressing MS?
Activity means a recent relapse or new inflammatory lesion on MRI. Progression means disability is gradually accumulating, so a person can have active disease, progression, both, or neither.
How do doctors decide whether my MS was progressive from the start?
They review the timing and pattern of your earliest symptoms, including whether you had sudden attacks followed by recovery or a gradual worsening from the beginning. Recent symptoms and MRI findings also help show whether the disease is currently active.
What medicines are used for progressive MS?
Disease-modifying therapies may slow disease change and reduce new inflammatory activity for some people. Ocrelizumab may be used for adults with PPMS, and siponimod may be used for active SPMS; the choice depends on disease activity and individual safety considerations.
Can treatment reverse disability from progressive MS?
Treatment can slow the disease and reduce new activity, but it rarely stops MS completely or reverses damage that has already occurred. Physical and occupational therapy, rehabilitation, and symptom care can help preserve function and quality of life.
Who should be on my progressive MS care team?
A multidisciplinary team may include a neurologist, physical therapist, occupational therapist, urologist, and other specialists. Working together, they can address daily concerns such as fatigue, mobility challenges, and spasticity.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Looking back at my history, was my condition progressive from the very beginning, or did it start with a clear relapsing-remitting phase?
  2. 2.Would you classify my MS right now as 'active' or 'non-active' based on my latest MRI and recent symptoms?
  3. 3.What specific goals should we set for my treatment—slowing progression, stopping new activity, or managing daily symptoms?
  4. 4.Who are the key members of the multidisciplinary team you recommend I connect with for my specific needs?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Toward Precision Phenotyping of Multiple Sclerosis.

    Pitt D, Lo CH, Gauthier SA, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2022; (9(6)) doi:10.1212/NXI.0000000000200025.

    PMID: 36041861
  2. 2

    The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.

    Sorensen PS, Sellebjerg F, Hartung HP, et al.

    Brain : a journal of neurology 2020; (143(9)):2637-2652 doi:10.1093/brain/awaa145.

    PMID: 32710096
  3. 3

    Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

    Jia X, Madireddy L, Caillier S, et al.

    Annals of neurology 2018; (84(1)):51-63 doi:10.1002/ana.25263.

    PMID: 29908077
  4. 4

    Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis.

    Blok KM, van Rosmalen J, Tebayna N, et al.

    Frontiers in neurology 2023; (14()):1277477 doi:10.3389/fneur.2023.1277477.

    PMID: 38020591
  5. 5

    Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).

    Pérez-Miralles F, Prefasi D, García-Merino A, et al.

    Multiple sclerosis and related disorders 2021; (50()):102860 doi:10.1016/j.msard.2021.102860.

    PMID: 33647591
  6. 6

    Ocrelizumab: A Review in Multiple Sclerosis.

    Syed YY

    CNS drugs 2018; (32(9)):883-890 doi:10.1007/s40263-018-0568-7.

    PMID: 30171504
  7. 7

    Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA.

    Ziemssen T, Hoffmann O, Klotz L, et al.

    JMIR research protocols 2020; (9(7)):e19598 doi:10.2196/19598.

    PMID: 32499214
  8. 8

    Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

    Montalban X, Hauser SL, Kappos L, et al.

    The New England journal of medicine 2017; (376(3)):209-220 doi:10.1056/NEJMoa1606468.

    PMID: 28002688
  9. 9

    Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.

    Gold R, Piani-Meier D, Kappos L, et al.

    Journal of neurology 2022; (269(9)):5093-5104 doi:10.1007/s00415-022-11166-z.

    PMID: 35639197
  10. 10

    Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America.

    Cristiano E, Rojas JI, Abad P, et al.

    Journal of the neurological sciences 2018; (393()):4-13 doi:10.1016/j.jns.2018.07.024.

    PMID: 30096568
  11. 11

    Progressive Multiple Sclerosis.

    Amezcua L

    Continuum (Minneapolis, Minn.) 2022; (28(4)):1083-1103 doi:10.1212/CON.0000000000001157.

    PMID: 35938658
  12. 12

    Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.

    Lizak N, Malpas CB, Sharmin S, et al.

    JAMA neurology 2020; (77(11)):1398-1407 doi:10.1001/jamaneurol.2020.2453.

    PMID: 32716480
  13. 13

    The window of opportunity for treatment of progressive multiple sclerosis.

    Sorensen PS, Fox RJ, Comi G

    Current opinion in neurology 2020; (33(3)):262-270 doi:10.1097/WCO.0000000000000811.

    PMID: 32251026

This page explains progressive MS classification and treatment for informational purposes only and does not constitute medical advice. Ask your neurologist and care team to interpret your history, MRI findings, and treatment options.

Get notified when new evidence is published on progressive relapsing multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.